Mie Azuma
Eisai
9 Papers
Mie Azuma is an academic researcher from Eisai. The author has contributed to research in topics: Medicine & Lenvatinib. The author has an hindex of 1, co-authored 5 publications.
Chat about Author
Papers
Economic Burden of Alzheimer's Disease Dementia in Japan.
Shunya Ikeda,Masaru Mimura,Manabu Ikeda,Kenji Wada-Isoe,Mie Azuma,Sachie Inoue,Kiyoyuki Tomita +6 more
TL;DR: In this paper, the authors estimated the annual healthcare and long-term care costs in fiscal year 2018 for adults over 65 years of age with ADD in Japan and the informal care costs and productivity loss for their families.
28
Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation
Ataru Igarashi,Mie Azuma,Quanwu Zhang,Weicheng Ye,A. Sardesai,Henry J. Folse,Ameya A. Chavan,Kiyoyuki Tomita,Amir Abbas Tahami Monfared +8 more
TL;DR: In this paper , a disease simulation model was used to evaluate the impact of lecanemab on disease progression in early AD based on data from the phase III CLARITY AD trial and published literature.
Comparative analysis of medical costs after hepatectomy versus radiofrequency ablation in patients with hepatocellular carcinoma in real‐world clinical practice
Takeshi Terashima,Y. Higashibeppu,Tatsuya Yamashita,Yukinori Sakata,Mie Azuma,Hiroaki Munakata,Mika Ishii,Shuichi Kaneko +7 more
TL;DR: The total medical costs and treatment outcomes in patients with primary hepatocellular carcinoma (HCC) are compared according to their initial treatment, that is, hepatectomy or radiofrequency ablation (RFA) in real‐world clinical practice in Japan.
2
Treatment patterns and medical costs after hepatectomy in real-world practice for patients with hepatocellular carcinoma in Japan.
Takeshi Terashima,Yoichi Higashibeppu,Tatsuya Yamashita,Yukinori Sakata,Mie Azuma,Kenichi Fujimoto,Hiroaki Munakata,Mika Ishii,Shuichi Kaneko +8 more
TL;DR: In this article, the authors examined the treatment patterns and medical costs in real-world practice among patients who received hepatectomy for hepatocellular carcinoma (HCC) in Japan.
2
Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: A model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents – CORRIGENDUM
Shunya Ikeda,Mie Azuma,Kenichi Fujimoto,Hidetoshi Shibahara,Sachie Inoue,Margaret Moline,Mika Ishii,Kazuo Mishima +7 more
TL;DR: In this article , a cost-effectiveness analysis of lemborexant for treating insomnia in Japan is presented, incorporating the risk of falls, motor vehicle collisions, and workplace accidents.